Document is current
Any future updates will be listed below
-
Authors
,
Yamamoto, Ryo
Fujishima, Seitaro http://orcid.org/0000-0001-8823-8440
Sasaki, Junichi
Gando, Satoshi
Saitoh, Daizoh
Shiraishi, Atsushi
Kushimoto, Shigeki
Ogura, Hiroshi
Abe, Toshikazu
Mayumi, Toshihiko
Kotani, Joji
Nakada, Taka-aki
Shiino, Yasukazu
Tarui, Takehiko
Okamoto, Kohji
Sakamoto, Yuichiro
Shiraishi, Shin-Ichiro
Takuma, Kiyotsugu
Tsuruta, Ryosuke
Masuno, Tomohiko
Takeyama, Naoshi
Yamashita, Norio
Ikeda, Hiroto
Ueyama, Masashi
Hifumi, Toru
Yamakawa, Kazuma
Hagiwara, Akiyoshi
Otomo, Yasuhiro
-
Funding
Funding for this research was provided by:
Japanese Association for Acute Medicine (2014-01)
- License Information
-
More Information
Article History
Received: 24 February 2021
Accepted: 16 April 2021
First Online: 29 April 2021
Declarations
:
: All collaborating hospitals obtained approval of their individual Institutional Review Board (IRB) for conducting research with human participants (approval number JAAM, 2014-01 from Japanese Association for Acute Medicine; approval number 014-0307 from Hokkaido University Graduate School of Medicine, head institute of the FORECAST group; and approval number 20150056 from the Keio University School of Medicine Keio, institute of the corresponding author).
: Not applicable.
: Dr. Fujishima reports grants and personal fees from Asahi Kasei Japan Co.; grants from Shionogi Co, Ltd.; grants from Chugai Pharmaceuticals Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd.; grants from Teijin Pharma, Ltd.; grants from Pfizer Inc.; grants from Tsumura & Co.; grants from Astellas Pharma Inc.; and personal fees from Takeda Pharmaceutical Co., Ltd., outside the submitted work. Dr. Gando reports personal fees from ASAHIKASEI PHARMA AMERICA, personal fees from ASAHIKASEI PHARMA JAPAN, and personal fees from GRIFOLS, outside the submitted work.
